decisionhealth Newsletters, Part B News - 2002 Issue 10 (October)
You may charge patient for self-injectable drug your provide
Subscribe or sign in to view the full article.
Article Overview
This article explains a CMS program memo addressing Medicare’s policy for self-injectable drugs, including when providers may bill patients for drugs they supply, how carriers determine coverage under the self-injectable drug policy, and what notice and transparency requirements apply. It is relevant to physicians, billing staff, and compliance professionals who need a general understanding of Medicare drug coverage policy updates and carrier implementation practices.
Why This Topic Matters
Providers and billing teams need to know how Medicare’s self-injectable drug policy affects coverage, patient billing, and carrier notice procedures. The article helps readers understand the general compliance and administrative implications of CMS guidance without relying on the full premium text.
What You Will Learn
- How CMS addresses Medicare coverage policy for self-injectable drugs
- What general notice and transparency expectations apply to carriers
- How provider billing considerations are discussed when drugs are excluded from coverage
- What role FDA labeling plays in the broader coverage determination context
Who Should Read This
- Physicians
- Medical billing and coding professionals
- Revenue cycle staff
- Compliance professionals
- Practice administrators
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com